Sodium zirconium cyclosilicate pretreatment for formula in vitro reduces potassium intake in infants with chronic kidney disease  

作　　者：Boxuan Liu Teng Wang Zhi Chen 

机构地区：[1]Department of Internal Medicine,Beijing Fu Xing Hospital,Capital Medical University,Beijing 100069,China [2]CAIQTEST(Beijing)Co.,Ltd.,Beijing 100176,China [3]Department of Nephrology,Beijing Children’s Hospital,Capital Medical University,National Center for Children’s Health,Beijing 100045,China

出　　处：《Chinese Medical Journal》2022年第24期3007-3009,共3页中华医学杂志（英文版）

摘　　要：To the Editor:Hyperkalemia is a common life-threatening complication of advanced chronic kidney disease(CKD)in infants.To manage hyperkalemia,dietary potassium intake restrictions is the most convenient,safe,and effective treatment.Kidney Disease Outcomes Quality Initiative(KDOQI)guideline recommends that the general restriction of potassium is 40 to 120 mg·kg^(-1)·day^(-1)for infants and 30 to 40 mg·kg^(-1)·day^(-1)for older children with CKD.

关 键 词：INTAKE KIDNEY KIDNEY 

分 类 号：R726.9[医药卫生—儿科]